| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi and Young Kyoung You |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Research Foundation of Korea |
2022R1I1A1A0106363612 |
| Korea Health Industry Development Institute |
HI23C1489 |
|
| Corresponding Author |
Jong Young Choi, MD, PhD, Professor, Department of Internal Medicine, The Catholic University of Korea, No. 222 Banpodaero, Seoul 06591, South Korea. jychoi@catholic.ac.kr |
| Key Words |
ABO-incompatible; Liver transplantation; Tacrolimus; Hepatocellular carcinoma |
| Core Tip |
Maintenance immunosuppression with calcineurin inhibitors (CNIs) such as tacrolimus or cyclosporine is the current standard regimen for liver transplantation (LT) patients, and this might be important in the preventing antibody-mediated rejection in ABO-incompatible (ABOi) LT. However, increased exposure to CNIs, especially in the first month after LT, is reported to be a risk factor for HCC recurrence. Nevertheless, the appropriate adjustment of immunosuppressant doses in ABOi LT recipients with and without HCC has not yet been determined. In this study, greater early exposure to tacrolimus was associated with HCC recurrence, whereas lesser exposures at later time points was associated with poorer long-term graft outcomes, suggesting that adjustment of serum tacrolimus concentration according to the presence of HCC may be required to improve graft outcomes. |
| Publish Date |
2023-12-27 12:41 |
| Citation |
Han JW, Choi JY, Jung ES, Kim JH, Cho HS, Yoo JS, Sung PS, Jang JW, Yoon SK, Choi HJ, You YK. Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation. World J Gastrointest Surg 2023; 15(12): 2727-2738 |
| URL |
https://www.wjgnet.com/1948-9366/full/v15/i12/2727.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v15.i12.2727 |
